Item 1(a). | Name of Issuer: |
Agile Therapeutics, Inc. (the “Issuer”)
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
101 Poor Farm Road, Princeton, New Jersey 08540
Item 2(a). | Names of Persons Filing: |
The names of the persons filing this report (collectively, the “Reporting Persons”) are:
Perceptive Advisors LLC (“Perceptive Advisors”)
Joseph Edelman (“Mr. Edelman”)
Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)
Item 2(b). | Address of Principal Business Office or, if None, Residence: |
The address of the principal business office of each of the Reporting Persons is:
51 Astor Place, 10th Floor
New York, NY 10003
Perceptive Advisors is a Delaware limited liability company
Mr. Edelman is a United States citizen
The Master Fund is a Cayman Islands corporation
Item 2(d). | Title of Class of Securities: |
Common stock, par value $0.0001 per share (“Common Stock”)
00847L 10 0
Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages are based on 59,302,126 outstanding shares of Common Stock as reported in the Issuer’s Form 10-Q filed on October 28, 2019 and an additional 5,000,000 shares purchased by the Master Fund in connection with the Issuer’s at the market offering.The Master Fund directly holds 11,919,925 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to